Eltrombopag post autologous hematopoietic stem cell transplant - an emerging indication in younger pediatric patients.

Categoría Estudio primario
RevistaAmerican journal of blood research
Año 2021
Cargando información sobre las referencias

BACKGROUND:

Engraftment of neutrophils and platelets after hematopoietic stem cell transplant (HSCT) is imperative for optimal outcomes. Eltrombopag has been used in adults after HSCT to boost platelet production. Its use in pediatric post HSCT patients has been limited.

METHODS:

The clinical and laboratory details of a post autologous HSCT patient were fetched by a retrospective review of the records.

RESULTS:

A 5-year old male child had primary thrombocytopenia post autologous HSCT for refractory Hodgkin lymphoma. Although the stem cell dose infused was adequate, the child had a delay in the engraftment of platelets. After ruling out the causes of post HSCT thrombocytopenia, eltrombopag was started for the child. With the use of eltrombopag, normal thrombopoiesis was restored in the child.

CONCLUSION:

Eltrombopag was effective and safe in overcoming post-HSCT primary thrombocytopenia in our patient.
Epistemonikos ID: 5660a3000170e72187b73d41a948601a0cd3e29d
First added on: Jul 06, 2022